Analytical Data
-
Gene name
SGCd
- Application
-
Alternative Names
35DAG; CMD1L; DAGD; SG-delta; SGCDP; SGD; 35kDa Dystrophin-Associated Glycoprotein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92629
-
Expression Region
Ile63~Leu289
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SGCd (Sarcoglycan delta) is a member of the sarcoglycan family, which plays a crucial role in the integrity and stability of the muscle cell membrane, particularly in skeletal and cardiac muscles. Mutations in the SGCd gene are associated with various muscular dystrophies, including limb-girdle muscular dystrophy (LGMD). Given the significant impact of these disorders on patient quality of life, there is a pressing need for effective therapies. Research into SGCd recombinant proteins focuses on understanding its structure, function, and interactions within the muscle membrane complex. Scientists aim to develop gene therapies or protein replacement strategies that can restore normal SGCd function in affected muscle tissues. Furthermore, studying SGCd's role in cellular signaling and muscle repair mechanisms can provide insights into potential therapeutic targets. Advances in recombinant protein technology enable the production of functional SGCd for use in preclinical models, paving the way for potential clinical applications. As research continues, SGCd reconstruction holds promise not only for treating LGMD but also for broader applications in muscular dystrophies and associated muscle disorders.
